Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 6,620 shares of the business's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total transaction of $363,040.80. Following the transaction, the chief executive officer now directly owns 549,867 shares in the company, valued at approximately $30,154,706.28. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Andrew Cheng also recently made the following trade(s):
- On Tuesday, June 10th, Andrew Cheng sold 37,837 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.05, for a total transaction of $2,045,089.85.
- On Monday, May 12th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.48, for a total value of $1,244,400.00.
- On Thursday, April 10th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $35.23, for a total transaction of $1,056,900.00.
Akero Therapeutics Stock Down 1.3%
Shares of AKRO traded down $0.70 during trading hours on Friday, reaching $54.20. The company's stock had a trading volume of 1,983,828 shares, compared to its average volume of 1,019,471. The company has a 50 day moving average of $45.88 and a two-hundred day moving average of $41.10. Akero Therapeutics, Inc. has a 1-year low of $21.02 and a 1-year high of $58.40. The firm has a market cap of $4.32 billion, a price-to-earnings ratio of -27.79 and a beta of -0.16. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Bank of America upped their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. HC Wainwright increased their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Finally, Citigroup reduced their price target on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $82.50.
Check Out Our Latest Analysis on AKRO
Institutional Investors Weigh In On Akero Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of AKRO. Northwest & Ethical Investments L.P. bought a new position in shares of Akero Therapeutics in the 1st quarter valued at approximately $32,000. GF Fund Management CO. LTD. bought a new stake in Akero Therapeutics during the fourth quarter valued at about $41,000. Sterling Capital Management LLC increased its stake in shares of Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after purchasing an additional 1,582 shares during the period. PNC Financial Services Group Inc. boosted its stake in Akero Therapeutics by 30.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after purchasing an additional 390 shares during the period. Finally, Quarry LP acquired a new position in shares of Akero Therapeutics during the fourth quarter worth approximately $83,000.
Akero Therapeutics Company Profile
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
